DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens today announced that, effective immediately, Walgreens Infusion Services will serve as a limited network home infusion provider for BLINCYTO™ (blinatumomab), a therapy for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). BLINCYTO™ can now be obtained through and administered by Walgreens Infusion Services. “Through our nationwide, community-based infusion